SHIN HEE SOON,신희순,KIM SEUNG YONG,김승용,SHIN DONG UK,신동욱,EOM JI EUN,엄지은,LEE SO YOUNG,이소영,JUNG SUN YOUNG,정선영,CHOI DAE WOON,최대운,NAM YOUNG DO,남영도,PARK SO LIM,박소림
申请号：
KR1020190109802
公开号：
KR1020200027454A
申请日:
2019.09.04
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
The present invention discloses a composition for ameliorating a pulmonary disease such as asthma, chronic obstructive pulmonary disease (COPD) or the like by using an extract of Hydrangea serrata. A food composition for reinforcing a respiratory function and ameliorating a respiratory disease comprises an extract of Hydrangea serrata as an active ingredient. The extract of Hydrangea serrata has activities of inhibiting Netosis activation of Neutrophil extracellular traps induced by phorbol myristate acetate (PMA), inhibiting expression of IL-8, i.e., inflammatory cytokines caused by CSE of NCI-H292 cells, i.e., a bronchial epithelial cell line, and inhibiting expression of MIP-2, i.e., inflammatory cytokines in MH-S cells that are alveolar macrophages activated by CES and lipopolysaccharide (LPS). Further, a respiratory disease mouse model having the extract of Hydrangea serrata injected thereinto exhibits activities of reducing the total cell number of BALF to not less than that of a group having Roflumilast (ROF), i.e., a positive control group, injected thereinto and inhibiting secretion of inflammatory cytokines and chemokines.COPYRIGHT KIPO 2020본 발명은 산수국 추출물을 이용한 천식 또는 만성폐쇄성 폐질환 등의 폐질환 개선용 조성물을 개시한다. 산수국 추출물은 PMA(phorbol myristate acetate)에 의해 유도된 호중구 세포외 트랩(Neutrophil extracellular traps)의 네토시스(Netosis) 활성화를 억제하고, 기관지 상피세포주인 NCI-H292 세포의 CSE에 의한 염증성 사이토카인인 IL-8의 발현을 억제하며, CES와 LPS(lipopolysaccaride)에 의해 활성된 폐포 대식세포 MH-S 세포에서 염증성 사이토카인인 MIP-2의 발현을 억제하는 활성을 가진다. 또한, 산수국 추출물을 투여한 호흡기 질환 마우스 모델에서는 양성 대조군인 Roflumilast(ROF)을 투여한 그룹 이상으로 BALF 총 세포수가 감소되며, 염증성 사이토카인과 케모카인 분비를 억제하는 활성을 나타낸다.
